Runben Biotechnology (SH:603193) Xin Lang Cai Jing·2025-08-19 01:36Core Insights - Runben Co., Ltd. (603193.SH) reported a total operating revenue of 895 million yuan for the first half of 2025, marking an increase of 151 million yuan compared to the same period last year, achieving a 20.31% year-on-year growth and three consecutive years of increase [1] - The net profit attributable to shareholders reached 188 million yuan, an increase of 7.5 million yuan year-on-year, reflecting a 4.16% growth and three consecutive years of increase [1] Financial Performance - The latest asset-liability ratio stands at 6.98%, a decrease of 0.70 percentage points from the previous quarter and a decrease of 2.03 percentage points from the same period last year [3] - The latest gross profit margin is 58.01%, an increase of 0.34 percentage points from the previous quarter [3] - The return on equity (ROE) is reported at 8.62% [3] - The diluted earnings per share (EPS) is 0.46 yuan, an increase of 0.02 yuan year-on-year, achieving a 4.55% growth and three consecutive years of increase [3] - The total asset turnover ratio is 0.39 times, an increase of 0.04 times year-on-year, reflecting a 12.26% growth [3] - The inventory turnover ratio is 3.00 times, an increase of 0.62 times year-on-year, achieving a 26.15% growth and two consecutive years of increase [3] Shareholder Structure - The number of shareholders is reported at 16,600, with the top ten shareholders holding a total of 327 million shares, accounting for 80.83% of the total share capital [3] - The largest shareholder is Guangzhou Zhuofan Investment Holdings Co., Ltd., holding 44.5 million shares [3]